Treace Medical Concepts, Inc. Common Stock TMCI
Analyst Ratings
- Consensus
- Hold — 1 Buy · 4 Hold · 1 Sell (6 analysts)
- Avg. Price Target
- $5.17 (+18.3% upside)
Key Stats
- Today's Range
- $4.25 – $4.40
- 50-Day Range
- $3.75 – $5.20
- 52-Week Range
- $1.17 – $7.78
- Volume
- 348K shs
- Average Volume
- 396K shs
- Market Cap
- $282.25 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 4.17
- Price / Sales
- 1.37
Short Interest
- Short Interest
- 0.08%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $205.31 million
- Net Income
- $-59,516,000
- Net Margin
- -28.99%
- Return on Equity
- -87.86%
- Debt-to-Equity
- 0.83
About Treace Medical Concepts, Inc. Common Stock
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
Related Stocks
Compare head-to-head: TMCI vs SYK·TMCI vs BSX·TMCI vs RMD·TMCI vs BAX
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.